Cannabidiol Effective for Reducing Drop Seizures in Lennox-Gastaut Syndrome Regardless of Clobazam Use

WASHINGTON, DC – Add-on cannabidiol (CBD) for the treatment of Lennox-Gastaut syndrome (LGS) produces a clinically meaningful reduction in drop seizures regardless of whether patients are receiving concomitant clobazam or valproic acid, according to results presented at the 2017 American Epilepsy Society Annual Meeting, December 1-5, 2017 in Washington, DC.

The post-hoc analysis, led by Elizabeth A. Thiele, MD, PhD, of Massachusetts General Hospital in Boston, included nonrandomized subgroups from the GWPCARE3 (ClinicalTrials.gov Identifier: NCT02224560) and GWPCARE4 (ClinicalTrials.gov Identifier: NCT02224690) trials, which demonstrated safety and efficacy of add-on CDB for patients with treatment-resistant LGS. The study was prompted by a bidirectional pharmacokinetic interaction between CBD and clobazam observed in previous trials.

The current analysis included 396 patients who were previously randomly assigned to receive 10 mg/d CBD (n=73), 20 mg/d CBD (n=162), or placebo (n=161). Of the cohort, 194 patients were on clobazam and 202

... read more at: https://www.neurologyadvisor.com/aes-2017/cannabidiol-seizure-reduction-lennox-gastaut-syndrome-concomitant-clobazam/article/711433/

by